Patient characteristics before and after PSM
| . | Before matching . | After matching . | ||
|---|---|---|---|---|
| De novo LBCL . | TriNHL . | De novo LBCL . | TriNHL . | |
| N = 391 . | N = 107 . | n = 85 . | n = 85 . | |
| Age at infusion, y | ||||
| Mean (SD) | 59.02 (13.769) | 62.11 (10.698) | 60.99 (11.800) | 61.80 (10.825) |
| Median | 63.00 | 64.00 | 63.00 | 64.00 |
| Min; max | 20.0; 82.0 | 17.0; 80.0 | 20.0; 78.0 | 17.0; 78.0 |
| Sex, n (%) | ||||
| Male | 253 (64.7) | 60 (56.1) | 48 (56.5) | 51 (60.0) |
| Female | 138 (35.3) | 47 (43.9) | 37 (43.5) | 34 (40.0) |
| CAR T-cell product, n (%) | ||||
| Tisa-cel | 140 (35.8) | 45 (42.1) | 29 (34.1) | 32 (37.6) |
| Axi-cel | 251 (64.2) | 62 (57.9) | 56 (65.9) | 53 (62.4) |
| LDH at lymphodepletion, n (%) | ||||
| Normal | 161 (41.9) | 36 (35.6) | 37 (44.6) | 31 (38.8) |
| More than the upper limit | 196 (51.0) | 55 (54.5) | 40 (48.2) | 43 (53.8) |
| Not measured | 27 (7.0) | 10 (9.9) | 6 (7.2) | 6 (7.5) |
| Missing | 7 | 6 | 2 | 5 |
| CRP at lymphodepletion, n (%) | ||||
| ≤30 mg/L | 268 (69.8) | 73 (71.6) | 62 (74.7) | 60 (74.1) |
| >30 mg/L | 80 (20.8) | 19 (18.6) | 16 (19.3) | 15 (18.5) |
| Not measured | 36 (9.4) | 10 (9.8) | 5 (6.0) | 6 (7.4) |
| Missing | 7 | 5 | 2 | 4 |
| ECOG PS at lymphodepletion, n (%) | ||||
| 0-1 | 317 (84.1) | 92 (91.1) | 70 (87.5) | 72 (88.9) |
| ≥2 | 60 (15.9) | 9 (8.9) | 10 (12.5) | 9 (11.1) |
| Missing | 14 | 6 | 5 | 4 |
| Ann Arbor stage at lymphodepletion, n (%) | ||||
| I | 36 (9.3) | 13 (12.3) | 9 (11.0) | 12 (14.3) |
| II | 44 (11.4) | 13 (12.3) | 12 (14.6) | 10 (11.9) |
| III | 35 (9.1) | 25 (23.6) | 19 (23.2) | 14 (16.7) |
| IV | 271 (70.2) | 55 (51.9) | 42 (51.2) | 48 (57.1) |
| Localized (I-II) | 80 (20.7) | 26 (24.5) | 21 (25.6) | 22 (26.2) |
| Disseminated (III-IV) | 306 (79.3) | 80 (75.5) | 61 (74.4) | 62 (73.8) |
| Missing | 5 | 1 | 3 | 1 |
| Number of previous lines of treatment, n (%) | ||||
| 2 | 261 (66.8) | 44 (41.1) | 44 (51.8) | 44 (51.8) |
| 3-4 | 119 (30.4) | 46 (43.0) | 34 (40.0) | 36 (42.4) |
| >4 | 11 (2.8) | 17 (15.9) | 7 (8.2) | 5 (5.9) |
| Bulk at lymphodepletion, n (%) | ||||
| No | 303 (77.5) | 80 (74.8) | 61 (71.8) | 64 (75.3) |
| Yes | 88 (22.5) | 27 (25.2) | 24 (28.2) | 21 (24.7) |
| Bridging and response to bridging, n (%) | ||||
| No | 47 (12.0) | 15 (14.0) | 10 (11.8) | 12 (14.1) |
| Yes | 344 (88.0) | 92 (86.0) | 75 (88.2) | 73 (85.9) |
| Complete response | 38 (11.1) | 8 (8.7) | 10 (13.3) | 7 (9.6) |
| Partial response | 70 (20.4) | 22 (23.9) | 14 (18.7) | 18 (24.7) |
| Stable disease | 47 (13.7) | 13 (14.1) | 12 (16.0) | 8 (11.0) |
| Progressive disease | 185 (53.9) | 48 (52.2) | 39 (52.0) | 39 (53.4) |
| Not evaluated | 3 (0.9) | 1 (1.1) | 0 (0.0) | 1 (1.4) |
| Missing | 48 | 15 | 10 | 12 |
| aaIPI score at lymphodepletion, n (%) | ||||
| 0 | 26 (7.1) | 8 (8.0) | 7 (9.1) | 6 (7.7) |
| 1 | 124 (33.7) | 33 (33.0) | 27 (35.1) | 26 (33.3) |
| 2 | 196 (53.3) | 47 (47.0) | 40 (51.9) | 36 (46.2) |
| 3 | 22 (6.0) | 12 (12.0) | 3 (3.9) | 10 (12.8) |
| Missing | 23 | 7 | 8 | 7 |
| . | Before matching . | After matching . | ||
|---|---|---|---|---|
| De novo LBCL . | TriNHL . | De novo LBCL . | TriNHL . | |
| N = 391 . | N = 107 . | n = 85 . | n = 85 . | |
| Age at infusion, y | ||||
| Mean (SD) | 59.02 (13.769) | 62.11 (10.698) | 60.99 (11.800) | 61.80 (10.825) |
| Median | 63.00 | 64.00 | 63.00 | 64.00 |
| Min; max | 20.0; 82.0 | 17.0; 80.0 | 20.0; 78.0 | 17.0; 78.0 |
| Sex, n (%) | ||||
| Male | 253 (64.7) | 60 (56.1) | 48 (56.5) | 51 (60.0) |
| Female | 138 (35.3) | 47 (43.9) | 37 (43.5) | 34 (40.0) |
| CAR T-cell product, n (%) | ||||
| Tisa-cel | 140 (35.8) | 45 (42.1) | 29 (34.1) | 32 (37.6) |
| Axi-cel | 251 (64.2) | 62 (57.9) | 56 (65.9) | 53 (62.4) |
| LDH at lymphodepletion, n (%) | ||||
| Normal | 161 (41.9) | 36 (35.6) | 37 (44.6) | 31 (38.8) |
| More than the upper limit | 196 (51.0) | 55 (54.5) | 40 (48.2) | 43 (53.8) |
| Not measured | 27 (7.0) | 10 (9.9) | 6 (7.2) | 6 (7.5) |
| Missing | 7 | 6 | 2 | 5 |
| CRP at lymphodepletion, n (%) | ||||
| ≤30 mg/L | 268 (69.8) | 73 (71.6) | 62 (74.7) | 60 (74.1) |
| >30 mg/L | 80 (20.8) | 19 (18.6) | 16 (19.3) | 15 (18.5) |
| Not measured | 36 (9.4) | 10 (9.8) | 5 (6.0) | 6 (7.4) |
| Missing | 7 | 5 | 2 | 4 |
| ECOG PS at lymphodepletion, n (%) | ||||
| 0-1 | 317 (84.1) | 92 (91.1) | 70 (87.5) | 72 (88.9) |
| ≥2 | 60 (15.9) | 9 (8.9) | 10 (12.5) | 9 (11.1) |
| Missing | 14 | 6 | 5 | 4 |
| Ann Arbor stage at lymphodepletion, n (%) | ||||
| I | 36 (9.3) | 13 (12.3) | 9 (11.0) | 12 (14.3) |
| II | 44 (11.4) | 13 (12.3) | 12 (14.6) | 10 (11.9) |
| III | 35 (9.1) | 25 (23.6) | 19 (23.2) | 14 (16.7) |
| IV | 271 (70.2) | 55 (51.9) | 42 (51.2) | 48 (57.1) |
| Localized (I-II) | 80 (20.7) | 26 (24.5) | 21 (25.6) | 22 (26.2) |
| Disseminated (III-IV) | 306 (79.3) | 80 (75.5) | 61 (74.4) | 62 (73.8) |
| Missing | 5 | 1 | 3 | 1 |
| Number of previous lines of treatment, n (%) | ||||
| 2 | 261 (66.8) | 44 (41.1) | 44 (51.8) | 44 (51.8) |
| 3-4 | 119 (30.4) | 46 (43.0) | 34 (40.0) | 36 (42.4) |
| >4 | 11 (2.8) | 17 (15.9) | 7 (8.2) | 5 (5.9) |
| Bulk at lymphodepletion, n (%) | ||||
| No | 303 (77.5) | 80 (74.8) | 61 (71.8) | 64 (75.3) |
| Yes | 88 (22.5) | 27 (25.2) | 24 (28.2) | 21 (24.7) |
| Bridging and response to bridging, n (%) | ||||
| No | 47 (12.0) | 15 (14.0) | 10 (11.8) | 12 (14.1) |
| Yes | 344 (88.0) | 92 (86.0) | 75 (88.2) | 73 (85.9) |
| Complete response | 38 (11.1) | 8 (8.7) | 10 (13.3) | 7 (9.6) |
| Partial response | 70 (20.4) | 22 (23.9) | 14 (18.7) | 18 (24.7) |
| Stable disease | 47 (13.7) | 13 (14.1) | 12 (16.0) | 8 (11.0) |
| Progressive disease | 185 (53.9) | 48 (52.2) | 39 (52.0) | 39 (53.4) |
| Not evaluated | 3 (0.9) | 1 (1.1) | 0 (0.0) | 1 (1.4) |
| Missing | 48 | 15 | 10 | 12 |
| aaIPI score at lymphodepletion, n (%) | ||||
| 0 | 26 (7.1) | 8 (8.0) | 7 (9.1) | 6 (7.7) |
| 1 | 124 (33.7) | 33 (33.0) | 27 (35.1) | 26 (33.3) |
| 2 | 196 (53.3) | 47 (47.0) | 40 (51.9) | 36 (46.2) |
| 3 | 22 (6.0) | 12 (12.0) | 3 (3.9) | 10 (12.8) |
| Missing | 23 | 7 | 8 | 7 |
aaIPI, age-adjusted International Prognostic Index; CR, complete response; CRP, C reactive protein; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; max, maximum; min, minimum; PS, performance status; SD, standard deviation.